Glycomine Bio

We are developing GLM101, a novel substrate replacement therapy for #PMM2CDG, a congenital disorder of #glycosylation and #raredisease.

[Glycomine Bio @GlycomineBio]

Glycomine announced today the first participant dosed in POLAR, our global, randomized, placebo-controlled Phase 2b study of GLM101 for the treatment of #PMM2CDG, a rare genetic disorder of glycosylation.

https://t.co/ZKMfTNpwdD

#CDGresearch #ClinicalTrial #RareDisease

[Glycomine Bio @GlycomineBio]

On #WorldCDGDay, we #StandUnited4CDG and remain focused on advancing GLM101, a potential disease-modifying therapy in #clinicaltrials for #PMM2CDG.

Learn about the science behind GLM101: https://t.co/bwk3Pf4ctu

For more on #CDGawareness: https://t.co/gY6IxlP5iC

[Glycomine Bio @GlycomineBio]

Honored to have our Series C milestone celebrated by @NYSE as we advance GLM101, the first disease-modifying therapy in development for #PMM2CDG, into a Phase 2b trial.

@MedCityNews explains the unmet need, and why this work matters: https://t.co/HkNpobQgXu

#CDGresearch

[Glycomine Bio @GlycomineBio]

We are excited to announce a $115 million Series C to advance GLM101, the first disease-modifying therapy in development for #PMM2CDG, into a Phase 2b clinical trial. Thank you to our new & existing investors for believing in our mission!

https://t.co/Nwnk1MKhYW

#CDGresearch

[Glycomine Bio @GlycomineBio]

We’re excited to announce that Joshua Grass has been appointed Chairperson of our Board of Directors. We welcome Josh at this pivotal point in our company’s growth as we advance GLM101 in #clinicaltrials for #PMM2CDG.

https://t.co/sLtNaPSXqc

#RareDiseases

[Glycomine Bio @GlycomineBio]

Glycomine is pleased to share that we have received FDA Fast Track Designation for GLM101, a potential treatment in #clinicaltrials for #PMM2CDG, a rare genetic disorder of glycosylation.

Read the release for more: https://t.co/KBXfTF3rLt

#CDGresearch #RareDisease #FastTrack

[Glycomine Bio @GlycomineBio]

We are proud to share two new research publications on GLM101, which is in development as the first potential disease-modifying treatment for #PMM2CDG.

Click here for free access thru 9/12: https://t.co/g4YJJkeSQ9

Open access: https://t.co/q412Y6s7Kw

#CDGresearch #rarediseases

[Glycomine Bio @GlycomineBio]

We’re excited to have presented data at the #RareDiseaseDay2024 Symposium, CDG Scientific and Family Conference showing encouraging efficacy from our ongoing #clinicaltrial of GLM101 in #PMM2CDG.

Read the release for more: https://t.co/tl31g8t2d5

#CDGresearch #RareDiseaseDay

[Glycomine Bio @GlycomineBio]

We are excited to announce that the first pediatric patient has been dosed in a Phase 2 clinical study of GLM101, which is in development as the first potential disease-modifying treatment for #PMM2CDG.

https://t.co/S0XAH7EINT

#CDGresearch #raredisease #clinicaltrials

[Glycomine Bio @GlycomineBio]

We are excited to have presented data at #ASHG23 from our ongoing natural history study, providing insights into genetic mutations and biomarkers for #PMM2CDG. The data will help design future #clinicaltrials for GLM101.

https://t.co/4hRjXSmLOf

#CDGresearch #raredisease

[Glycomine Bio @GlycomineBio]

Today we welcome Dr. Rose Marino as our CMO, bringing 20+ years of combined experience in pediatric endocrinology and clinical research. She joins us as we advance in #clinicaltrials GLM101, a potential disease-modifying treatment for #PMM2CDG.

https://t.co/CzC0pFPhb8

[Glycomine Bio @GlycomineBio]

Today we announce the first patient dosed in a phase 2 #clinicaltrial of GLM101, our lead drug candidate. We look forward to advancing the development of the first potential disease-modifying therapy to be evaluated in #PMM2CDG.

https://t.co/lUlAgkzl9X

#raredisease

[Glycomine Bio @GlycomineBio]

We are excited to welcome Steven Axon as CEO and Jacqueline Grant and Jason Hafler to our BOD. Their appointments come at a pivotal stage as we advance GLM101, a potential disease-modifying treatment for #PMM2CDG, in clinical trials.

https://t.co/w95mdCFJFk

[Glycomine Bio @GlycomineBio]

Today is #WorldCDGDay, and we are raising awareness for #CDGresearch. We #StandUnited4CDG and are committed to developing new #PMM2CDG therapies to improve the quality of life for people with this #raredisease.

Learn more: https://t.co/joI7LgC2r8

#CDGawareness #rarediseases

[Glycomine Bio @GlycomineBio]

#RareDiseaseDay is today. We are dedicated to developing meaningful new #PMM2CDG therapies and improving the quality of life for #raredisease patients, families, and caregivers.

Learn more here: https://t.co/bwk3Pf4Kj2

#PMM2CDG #glycosylation #CDGawareness #rarediseases

[Glycomine Bio @GlycomineBio]

#RareDiseaseDay is Monday, and there are events all over the world to raise awareness for patients and their families affected by #rarediseases.

Learn more about this day and find an event here: https://t.co/dQjP7GiOi3

#CDGawareness @rarediseaseday

[Glycomine Bio @GlycomineBio]

We have two open positions Sr. Director, Analytical #Chemistry and Sr. Scientist, Molecular and Cellular #Biology #Research. Are you dedicated to helping find new therapeutic options for patients with #rarediseases? Come work with us!

Learn more https://t.co/ctmlv7pfyW

#careers

[Glycomine Bio @GlycomineBio]

We just posted a #job opening for Sr. #Scientist, Molecular and Cellular #Biology #Research. We are dedicated to helping find new therapeutic options for patients with #rarediseaes. Come work with us!

Learn more at: https://t.co/ctmlv7pfyW

#biotech #careers

[Glycomine Bio @GlycomineBio]

Glycomine Announces First Dosing in Phase 1 Clinical Study of GLM101, a Potential Treatment for PMM2-CDG

https://t.co/krXeYr6nmv

#PMM2CDG #clinicaltrials #clinicaltrial #glycosylation #glycoprotein #glycans #glycosylated #glycoresearch #CDGresearch #CDGawareness #raredisease

[Glycomine Bio @GlycomineBio]

Congrats @MissionBioCap for closing your latest round of funding! We are inspired by your continued commitment to supporting early-stage life science companies with impactful science and technologies.

#venturecapital #lifesciences #bayarea #biotech

[Mission BioCapital @MissionBioCap]

We are thrilled to announce Mission BioCapital V, a $275M fund focused on investing in early stage life science companies! Investing in @MBiolabs, @labcentral, @biolabs companies and company creation. Reach out to learn more!
https://t.co/nFt90jh8Rt